PCT

OCT 2 0 2003

INTERNATIONAL SEARCH REPORT


R & D COUNSEL

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference		Transmittal of International Search Report
2380F PCT	ACTION (Form PC1/ISA/2)	20) as well as, where applicable, item 5 below.
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/US 03/11769	16/04/2003	03/05/2002
Applicant		
ALCON, INC.		
This International Search Report has been according to Article 18. A copy is being tra	n prepared by this International Searching Auth Insmitted to the International Bureau.	ority and is transmitted to the applicant
This International Search Report consists		
X It is also accompanied by	a copy of each prior art document cited in this	report.
Basis of the report		
With regard to the language, the is language in which it was filed, unle	nternational search was carried out on the bas ess otherwise indicated under this item.	is of the international application in the
the international search was Authority (Rule 23.1(b)).	as carried out on the basis of a translation of th	e international application furnished to this
 b. With regard to any nucleotide and was carried out on the basis of the 	d/or amino acid sequence disclosed in the interesting in the sequence listing :	ernational application, the international search
	nal application in written form.	
filed together with the inter	national application in computer readable form	•
	this Authority in written form.	
	this Authority in computer readble form.	
the statement that the sub international application as	sequently furnished written sequence listing do s filed has been furnished.	es not go beyond the disclosure in the
the statement that the information furnished	rmation recorded in computer readable form is	identical to the written sequence listing has been
2. X Certain claims were foun	d unsearchable (See Box I).	
3. Unity of invention is lack	ing (see Box II).	
4. With regard to the title,		
the text is approved as sub	omitted by the applicant.	
X the text has been establish	ed by this Authority to read as follows:	
METHOD OF TREATING VASO	CULAR ENDOTHELIAL GROWTH FAC	TOR MEDIATED VASCULAR
DISORDERS USING AMFEN	AC OR NEPAFENAC	
5. With regard to the abstract,		
the text is approved as sub	mitted by the applicant	
the text has been establish	ed, according to Rule 38.2(b), by this Authority date of mailing of this international search repo	as it appears in Box III. The applicant may, rt, submit comments to this Authority.
6. The figure of the drawings to be publis	shed with the abstract is Figure No.	1
as suggested by the application	ant.	None of the figures.
because the applicant faile	d to suggest a figure.	
because this figure better o	haracterizes the invention.	·

INTERNATIONAL SEARCH REPORT





A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/165 A61K31/196 A61P27/02 A61P27/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) I PC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)


EPO-Internal, MEDLINE, BIOSIS, PAJ, WPI Data, EMBASE, PASCAL, CHEM ABS Data

C. DOCUMI	ENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2002/037929 A1 (GRAFF GUSTAV ET AL) 28 March 2002 (2002-03-28) column 2-3 example 1 claims 1-9	1-10
X,P	TAKAHASHI KYOICHI ET AL: "Topical nepafenac inhibits ocular neovascularization." INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. UNITED STATES JAN 2003, vol. 44, no. 1, January 2003 (2003-01), pages 409-415, XP009013970 ISSN: 0146-0404 page 409 page 412-414	1-10

Y Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
Special categories of cited documents: 'A' document defining the general state of the art which is not considered to be of particular relevance.	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 'E' earlier document but published on or after the international filing date 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) 'O' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the international filing date but later than the priority date claimed 	 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. '&' document member of the same patent family
Date of the actual completion of the international search 6 October 2003	Date of mailing of the international search report 17/10/2003
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nt, Fax: (+31-70) 340-3016	Authorized officer Domingues, H

7

INTERNATIONAL SEARCH REPORT



C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Citation of document, with indication, where appropriate, of the relevant passages X,P DATABASE BIOSIS 'Online! 1-10 BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2002 PENN J S ET AL: "Studies of the Effect and Mechanism of Action of Topical Nepafenac in a Rat Model of ROP." Database accession no. PREV200300154861 XP002247860 abstract & ARVO ANNUAL MEETING ABSTRACT SEARCH AND PROGRAM PLANNER, vol. 2002, 2002, page Abstract No. 2741 Annual Meeting of the Association For Research in Vision and Ophthalmology; Fort Lauderdale, Florida, USA; May 05-10, 2002 X,P DATABASE BIOSIS 'Online! 1 - 10BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2002 BINGAMAN D P ET AL: "Topical Ocular Delivery of Nepafenac Inhibits Preretinal Neovascularization." Database accession no. PREV200300165352 XP002247861 abstract & ARVO ANNUAL MEETING ABSTRACT SEARCH AND PROGRAM PLANNER, vol. 2002, 2002, page Abstract No. 3920 Annual Meeting of the Association For Research in Vision and Ophthalmology; Fort Lauderdale, Florida, USA; May 05-10, 2002 Υ KWAK N ET AL: "VEGF is major stimulator 1-10 in model of choroidal neovascularization." INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. UNITED STATES SEP 2000, vol. 41, no. 10, September 2000 (2000-09), pages 3158-3164, XP009013972 ISSN: 0146-0404 page 3161 -page 3162 Υ WO 01 15744 A (BRIGHAM & WOMENS HOSPITAL) 1-10 8 March 2001 (2001-03-08) page 9 page 3 A,P WO 02 078681 A (ALCON INC ; GRAFF GUSTAV 1-10 (US); HELLBERG MARK R (US); YANNI JOHN M () 10 October 2002 (2002-10-10) page 5 example 2

7

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1 and 3 refer to vascular diseases defined by reference to a biological mechanism — vascular endothelial growth factor mediated vascular disorders. The claims cover all the conditions mediated by this mechanism, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such conditions. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely for the search term "vascular disorders" and for the diseases mentioned in claims 2 and 4.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.



ernational application No. PCT/US 03/11769

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1.	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. X	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: see FURTHER INFORMATION sheet PCT/ISA/210
з. 🗌	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	emational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark o	on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

INTEPNATIONAL SEARCH REPORT

ion on patent family members

US 03/11769

Patent document dted in search report		Publication date		Patent family member(s)	Publication date
US 2002037929	A1	28-03-2002	AU	8333701 A	25-02-2002
			CA	2417282 A1	21-02-2002
			EP	1309323 A2	14-05-2003
			WO	0213804 A2	21-02-2002
WO 0115744	A	08-03-2001	AU	7110300 A	26-03-2001
			CA	2381926 A1	08-03-2001
			EP	1212101 A1	12-06-2002
			JР	2003508453 T	04-03-2003
			WO	0115744 A1	08-03-2001
WO 02078681 A	Α	10-10-2002	WO	02078681 A2	10-10-2002
			US	2002183376 A1	05-12-2002